Dr. Heimbach is a Senior Principal Scientist at Merck & Co., Inc., Rahway, NJ, USA in the Biologics Development and Biopharmaceutics Group which is part of the Sterile and Specialty Products Group. There he serves as a biopharmaceutics and PBBM/PBPK expert in oral and long-acting injectables drug development, which includes establishing the bioequivalence safe space of new drug candidates. Prior to that Tycho was Director in DMPK at Novartis where he led a global PBPK modeling group. Tycho served as cochair on working groups for the PBPK Modeling and the PBPK renal and hepatic impairment WG and the PBBM WG for the Innovation and Quality in Pharmaceutical Development (IQ) consortium. He is currently serving as the Merck & Co., Inc., representative on the PBBM Innovation & Quality (IQ) Consortium Working Group. Dr. Heimbach has been a speaker at 60 national and international conferences. He has authored/coauthored ~65 peer-reviewed publications in ADME, PBPK and formulation sciences and was recognized as an AAPS Fellow in 2021.